Canaccord Genuity Maintains Buy Rating on Alnylam Pharmaceuticals, Inc. (ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the 10 Unstoppable Stocks to Buy and Hold for the Next 3 Years.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the Unstoppable Stocks to Buy and Hold for the Next 3 Years. On February 17, analyst Whitney Ijem from Canaccord Genuity maintained a “Buy” rating on the company’s stock with a price objective of $429.00. The analyst’s rating is supported by the factors related to Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s execution and growth outlook.

The analyst noted that the roll-out of AMVUTTRA in transthyretin-mediated amyloidosis continues to outperform initial expectations. The current sales are approximately double of what the broader market expected at the time of approval. Also, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s company guidance reflected continued robust expansion of top-line into 2026.

In a different release, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its consolidated financial results for Q4 2025 and FY 2025. The company highlighted approval of AMVUTTRA for ATTR-CM in the U.S., fueling its total net product revenues of ~$3 billion, or 81% YoY growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution.

While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 High-Flying Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.